NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to ...
Today, the US Food and Drug Administration (FDA) approved prademagene zamikeracel cellular sheets (pz-cel, Zevaskyn), the first autologous cell-based gene therapy for treating wounds in adults and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEB Literature review of 65 studies confirms and expands understanding of substantial ...
In a recently published phase 3 trial, credit card-sized cultured skin grafts corrected for the COL7A1 mutation that causes recessive dystrophic epidermolysis bullosa (RDEB) and enabled most patients ...
The last time I spoke about Abeona Therapeutics (ABEO), it was with a Seeking Alpha article entitled "Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn." With respect to ...
Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results